Scott Lyman

Scott Lyman, CEO and Co-Founder of Belhaven Biopharma, champions the mission of delivering accessible health care worldwide, with a particular focus on innovative allergy care. As Chairman of the Board, his leadership is rooted in a dedication to developing cutting-edge pharmaceutical solutions that address severe allergies through user-friendly dry powder nasal formulations. His extensive experience in the biopharmaceutical sector, including pivotal roles at GSK, BioCryst, Salix, and as Chief Business Officer at Grid Therapeutics, underpins his commitment to transforming emergency medication delivery systems. Scott's academic background in chemical engineering and business administration bolsters his ability to drive forward the global accessibility of essential medications.

Speaking Topics:
• Global Health Care Accessibility: Strategies for delivering essential allergy treatments worldwide.
• Innovations in Allergy Care: Developing and deploying user-friendly severe allergy treatments.
• Overcoming Pharmaceutical Challenges: Lessons from global regulatory landscapes and market dynamics.
• Leadership for Global Health Impact: Fostering innovation and strategic growth in the pursuit of accessible health care.